# Trever G Bivona

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 79 papers | 11,139 citations | 81900 39 h-index | 69250 77 g-index |
| 86 all docs | 86 docs citations | 86 times ranked | 18010 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Evolution of metastasis: new tools and insights. Trends in Cancer, 2022, 8, 98-109. | 7.4 | 40 |
| 2 | Inhibition of SHP2 as an approach to block RAS-driven cancers. Advances in Cancer Research, 2022, 153, 205-236. | 5.0 | 7 |
| 3 | Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine, 2022, 14, eabc7480. | 12.4 | 14 |
| 4 | Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185, 1905-1923.e25. | 28.9 | 108 |
| 5 | Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, . | 8.2 | 15 |
| 6 | Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science, 2021, 371, . | 12.6 | 166 |
| 7 | Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell, 2021, 184, 2649-2664.e18. | 28.9 | 102 |
| 8 | Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology, 2021, 62, 1-12. | 6.1 | 83 |
| 9 | Stepwise evolution of therapy resistance in AML. Cancer Cell, 2021, 39, 904-906. | 16.8 | 3 |
| 10 | Targeting AXL in NSCLC. Lung Cancer: Targets and Therapy, 2021, Volume 12, 67-79. | 2.7 | 8 |
| 11 | Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Reports, 2021, 36, 109491. | 6.4 | 11 |
| 12 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662. | 1.1 | 274 |
| 13 | Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments, 2021, , . | 0.3 | 2 |
| 14 | Co-occurring Alterations in the RASâ€“MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 439-449. | 7.0 | 64 |
| 15 | Acquired Resistance in Lung Cancer. Annual Review of Cancer Biology, 2020, 4, 279-297. | 4.5 | 13 |
| 16 | Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis, 2020, 9, 102. | 4.9 | 24 |
| 17 | Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nature Communications, 2020, 11, 3675. | 12.8 | 63 |
| 18 | Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. Cancer Letters, 2020, 493, 217-227. | 7.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell, 2020, 182, 1232-1251.e22. | 28.9 | 371 |
| 20 | EGFR targeted therapy resistance: current status, challenges, and future outlook. Journal of Thoracic Disease, 2020, 12, 2849-2850. | 1.4 | 2 |
| 21 | Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623. | 1.1 | 43 |
| 22 | Targeting Oncogenic BRAF: Past, Present, and Future. Cancers, 2019, 11, 1197. | 3.7 | 143 |
| 23 | Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Reports, 2019, 28, 2317-2330.e8. | 6.4 | 12 |
| 24 | BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers, 2019, 11, 1381. | 3.7 | 44 |
| 25 | Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine, 2019, 25, 185-197. | 6.7 | 118 |
| 26 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427. | 8.5 | 46 |
| 27 | Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discovery, 2019, 9, 587-604. | 9.4 | 13 |
| 28 | Dampening oncogenic RAS signaling. Science, 2019, 363, 1280-1281. | 12.6 | 25 |
| 29 | Polytherapy and Targeted Cancer Drug Resistance. Trends in Cancer, 2019, 5, 170-182. | 7.4 | 183 |
| 30 | Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports, 2019, 21, 21. | 4.0 | 82 |
| 31 | Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer, 2019, 20, e137-e141. | 2.6 | 8 |
| 32 | Immunohistochemistry to Study YAP in Human Tissue Samples. Methods in Molecular Biology, 2019, 1893, 89-95. | 0.9 | 6 |
| 33 | Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature Medicine, 2019, 25, 111-118. | 30.7 | 196 |
| 34 | Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research, 2019, 79, 546-556. | 0.9 | 59 |
| 35 | Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10. | 28.9 | 2,111 |
| 36 | BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15. | 3.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of Thoracic Disease, 2018, 10, S4061-S4064. | 1.4 | 2 |
| 38 | The evolving understanding of immunoediting and the clinical impact of immune escape. Journal of Thoracic Disease, 2018, 10, 1248-1252. | 1.4 | 10 |
| 39 | Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268. | 1.1 | 515 |
| 40 | RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology, 2018, 20, 1064-1073. | 10.3 | 276 |
| 41 | TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Journal of Clinical Investigation, 2018, 128, 2500-2518. | 8.2 | 73 |
| 42 | Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Annals of Translational Medicine, 2018, 6, 160-160. | 1.7 | 22 |
| 43 | Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer. Cancer Research, 2017, 77, 1200-1211. | 0.9 | 11 |
| 44 | CD74 - ROS1 Fusion in NSCLCÂDetected by Hybrid Captureâ€“Based Tissue Genomic Profiling and ctDNA Assays. Journal of Thoracic Oncology, 2017, 12, e19-e20. | 1.1 | 6 |
| 45 | Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. Npj Precision Oncology, 2017, 1, . | 5.4 | 70 |
| 46 | A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist, 2017, 22, 768-773. | 3.7 | 33 |
| 47 | Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports, 2017, 7, 44206. | 3.3 | 28 |
| 48 | Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658. | 28.4 | 679 |
| 49 | Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications, 2017, 8, 823. | 12.8 | 53 |
| 50 | Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, . | 6.3 | 128 |
| 51 | Current Landscape of Targeted Therapy in Lung Cancer. Clinical Pharmacology and Therapeutics, 2017, 102, 757-764. | 4.7 | 134 |
| 52 | Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704. | 21.4 | 423 |
| 53 | Inactivation of Capicua drives cancer metastasis. Nature Genetics, 2017, 49, 87-96. | 21.4 | 130 |
| 54 | Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410. | 12.8 | 117 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Dividing and conquering the variation among variants in EML4-ALK lung cancer. Translational Cancer Research, 2017, 6, S369-S370. | 1.0 | 0 |
| 56 | Neoadjuvant Oncogene-Targeted Therapy in Early Stage Nonâ€“Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer, 2016, 17, 466-469. | 2.6 | 16 |
| 57 | RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Molecular and Cellular Oncology, 2016, 3, e1091061. | 0.7 | 7 |
| 58 | A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 2016, 22, 472-478. | 30.7 | 145 |
| 59 | Combined chemicalâ€“genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9015-9020. | 7.1 | 33 |
| 60 | Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13456-13461. | 7.1 | 65 |
| 61 | An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters, 2016, 380, 144-152. | 7.2 | 26 |
| 62 | The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Molecular and Cellular Oncology, 2016, 3, e1021441. | 0.7 | 29 |
| 63 | RAS signaling in ALK fusion lung cancer. Small GTPases, 2016, 7, 32-33. | 1.6 | 20 |
| 64 | Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discovery, 2016, 6, 14-16. | 9.4 | 14 |
| 65 | Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFÎ²2-bioenergetics-mitochondrial priming. Oncotarget, 2016, 7, 82013-82027. | 1.8 | 23 |
| 66 | AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer: Targets and Therapy, 2015, 6, 27. | 2.7 | 18 |
| 67 | AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells. PLoS ONE, 2015, 10, e0119832. | 2.5 | 28 |
| 68 | RAS-MAPK in ALK targeted therapy resistance. Cell Cycle, 2015, 14, 3661-3662. | 2.6 | 12 |
| 69 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256. | 21.4 | 434 |
| 70 | Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery, 2015, 5, 1040-1048. | 9.4 | 226 |
| 71 | NF-Î°B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Reports, 2015, 11, 98-110. | 6.4 | 178 |
| 72 | AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546. | 16.8 | 263 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALKâ€“positive lung cancer. Nature Medicine, 2015, 21, 1038-1047. | 30.7 | 245 |
| 74 | Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E748-57. | 7.1 | 90 |
| 75 | Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. Journal of Translational Medicine, 2014, 12, 355. | 4.4 | 18 |
| 76 | Recent advances in personalized lung cancer medicine. Personalized Medicine, 2014, 11, 309-321. | 1.5 | 22 |
| 77 | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 2012, 44, 852-860. | 21.4 | 1,049 |
| 78 | FAS and NF-ÎºB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471, 523-526. | 27.8 | 374 |
| 79 | Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biology, 2002, 4, 343-350. | 10.3 | 582 |